New pain block could cut opioid use after gynecologic cancer surgery

NCT ID NCT07458295

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a long-acting numbing drug (liposomal bupivacaine) combined with standard bupivacaine can provide better pain relief after laparoscopic surgery for gynecologic cancers. About 110 adults undergoing such surgery will receive either the combination or standard care via an ultrasound-guided abdominal wall injection. The main goal is to see if patients need less morphine in the first 48 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
liposomal bupivacaine plus bupivacaine
What this could lead to
If it works, this could provide a longer-lasting pain block after surgery, reducing the need for strong opioid painkillers and speeding recovery.
What could go wrong
This is a relatively small, early-stage trial (110 participants) testing a drug already used in other surgeries. The benefit may be modest or not better than standard care, and any new drug carries risks of side effects like allergic reaction or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNECOLOGIC ONCOLOGY PATIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.